Observational study for evaluation of quality of life [QOL] in patients under treatment for B-CLL.

Trial Profile

Observational study for evaluation of quality of life [QOL] in patients under treatment for B-CLL.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2013

At a glance

  • Drugs Alemtuzumab; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms Vitalis
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2009 Alemtuzumab, fludarabine added as drug descriptors as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Bayer Company added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Actual patient number (300) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top